Table 1. Cardiac morphology and hemodynamics at the end of study.
| Parameters | Sham | Infarction treated with | ||||
| Vehicle | Vehicle | OM | OM + Vit C | OM + ARB | FM | |
| No. of rats | 10 | 10 | 11 | 11 | 12 | 10 |
| Body weight, g | 315 ± 12 | 311 ± 11 | 325 ± 13 | 314 ± 10 | 324 ± 12 | 326 ± 14 |
| Heart rate, bpm | 383 ± 14 | 405 ± 15 | 397 ± 12 | 407 ± 12 | 374 ± 16 | 387 ± 16 |
| LVESP, mmHg | 110 ± 5 | 97 ± 10 | 96 ± 8 | 105 ± 6 | 102 ± 10 | 97 ± 7 |
| LVEDP, mmHg | 7 ± 3 | 18 ± 2* | 19 ± 4* | 16 ± 5* | 15 ± 5* | 17 ± 5* |
| +dP/dt, mmHg/s | 8052 ± 418 | 2482 ± 264* | 2241 ± 249*# | 4142 ± 352*#† | 3798 ± 262*#† | 2624 ± 342*† |
| -dP/dt, mmHg/s | 6873 ± 305 | 2402 ± 234* | 2135 ± 242*# | 3222 ± 316*#† | 2982 ± 265*#† | 2592 ± 308*† |
| Infarct size, % | -- | 40 ± 4 | 41 ± 2 | 42 ± 4 | 40 ± 3 | 41 ± 3 |
| LVW/BW, mg/g | 2.13 ± 0.20 | 3.04 ± 0.25* | 2.95 ± 0.26* | 2.87 ± 0.35* | 2.83 ± 0.37* | 2.98 ± 0.38* |
| RVW/BW, mg/g | 0.51 ± 0.11 | 0.64 ± 0.10* | 0.75 ± 0.11*# | 0.55 ± 0.09#† | 0.58 ± 0.08† | 0.62 ± 0.13*† |
| LungW/BW, mg/g | 4.05 ± 0.37 | 5.27 ± 0.38* | 5.96 ± 0.33*# | 4.52 ± 0.32#† | 4.93 ± 0.35*#† | 4.95 ± 0.43*† |
Values are mean ± SD.
ADMA, asymmetric dimethylarginine; ARB, olmesartan; BW, body weight; LungW, lung weight; FM, famotidine; LVEDP, left ventricular end-diastolic pressure; LVESP, left ventricular end-systolic pressure; LVW, left ventricular weight; OM, omeprazole; RVW, right ventricular weight; Vit C, vitamin C.
* p < 0.05 compared with sham; # p < 0.05 compared with infarcted group treated with vehicle; † p < 0.05 compared with infarcted group treated with OM.